Feasibility and Acceptability of Collecting Passive Smartphone Data for Potential Use in Digital Phenotyping Among Family Caregivers and Patients With Advanced Cancer Calibration-free odds type ...
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...
Proposals for the Implementation of a Multidimensional Platform That Allows the Advancement of Oncology Nursing in the Latin American Environment (The INCREASE Proposal) In response to the challenges ...
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...
Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study Of the analyzed data from 70 patients with ...
Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care ...
Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...
In 2012, the US National Cancer Institute added a requirement that all NCI-Designated Clinical and Comprehensive Cancer Centers identify a population-based and geographically defined catchment area to ...
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas Larotrectinib is a ...
Efficacy and safety of intraperitoneal paclitaxel based regimens in patients with gastric cancer and peritoneal metastasis: A systematic review and meta-analysis. Envafolimab in combination with ...
Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). Single-cycle neoadjuvant ...
PK/PD analyses of circulating tumor DNA (ctDNA) in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback